Limiting factors in successful preservation of cadaveric kidneys with ischemia time exceeding 50 hours. 1987

G M Abouna, and M S Samhan, and M S Kumar, and A G White, and O S Silva

The results of 61 cadaveric allografts preserved for 30 to 76 hours were analyzed to determine the effect of cold ischemia time, the method of preservation, and the type of immunosuppression on early graft viability and long-term graft survival. Preservation in cold storage up to 50 hours gave a low incidence of nonfunction (4%) and of posttransplant dialysis (20%) and a high rate of function both at 1 month (96%) and at 2 years (60%). Cold ischemia time greater than 50 hours caused a significantly increased need for dialysis (58%) but without appreciable difference in graft function at 1 month or at 2 years. Preservation by machine had no advantage over preservation by simple cold storage when the cold ischemia time was less than 50 hours. When cold ischemia time exceeded 50 hours, machine preservation was associated with a significantly reduced incidence of posttransplant dialysis but without significant differences in long-term function at 2 years. With up to 50 hours of cold ischemia and providing there was no ATN, CsA had little nephrotoxicity and gave excellent graft function at 1 month and at 2 years. However, the nephrotoxicity of CsA was markedly increased when the preservation interval exceeded 50 hours, resulting in a significantly increased rate of primary nonfunction and the need for dialysis with a significant decrease in graft function at 1 month and at 2 years. The nephrotoxicity of CsA was considerably decreased or eliminated without affecting its powerful immunosuppressive property when initial immunosuppression was begun with azathioprine with sequential conversion to CsA when graft function was fully established. It is recommended that when cold ischemia is long or when there is ATN, CsA should be used as a sequential therapy to azathioprine after graft diuresis or, alternatively, in much smaller doses as part of a combination therapy with azathioprine.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007511 Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION. Ischemias
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D002102 Cadaver A dead body, usually a human body. Corpse,Cadavers,Corpses
D003080 Cold Temperature An absence of warmth or heat or a temperature notably below an accustomed norm. Cold,Cold Temperatures,Temperature, Cold,Temperatures, Cold
D003524 Cyclosporins A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001379 Azathioprine An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed) Azathioprine Sodium,Azathioprine Sodium Salt,Azathioprine Sulfate,Azothioprine,Immuran,Imuran,Imurel,Sodium, Azathioprine
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

G M Abouna, and M S Samhan, and M S Kumar, and A G White, and O S Silva
December 1972, Transplantation,
G M Abouna, and M S Samhan, and M S Kumar, and A G White, and O S Silva
March 2019, Translational andrology and urology,
G M Abouna, and M S Samhan, and M S Kumar, and A G White, and O S Silva
February 1987, Transplantation proceedings,
G M Abouna, and M S Samhan, and M S Kumar, and A G White, and O S Silva
January 1987, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
G M Abouna, and M S Samhan, and M S Kumar, and A G White, and O S Silva
May 1970, The British journal of surgery,
G M Abouna, and M S Samhan, and M S Kumar, and A G White, and O S Silva
April 1990, Transplantation proceedings,
G M Abouna, and M S Samhan, and M S Kumar, and A G White, and O S Silva
April 1976, Surgery,
G M Abouna, and M S Samhan, and M S Kumar, and A G White, and O S Silva
August 1990, Transplantation proceedings,
G M Abouna, and M S Samhan, and M S Kumar, and A G White, and O S Silva
October 1983, Archives of surgery (Chicago, Ill. : 1960),
G M Abouna, and M S Samhan, and M S Kumar, and A G White, and O S Silva
January 1980, Human pathology,
Copied contents to your clipboard!